Clinical Trials
22 trialsNCT04618913 2026-05-26
VICTORIE
Pfizer
Active not recruiting
NCT06886516 2026-04-15
Apixaban in Thrombocytopenia
Beth Israel Deaconess Medical Center
Phase EARLY_PHASE1 Recruiting
NCT07493304 2026-03-25
ROXI-CAT-II
Regeneron Pharmaceuticals
Phase 3 Not yet recruiting
NCT05171049 2026-02-23
ASTER
Anthos Therapeutics, Inc.
Phase 3 Terminated
NCT07005024 2026-02-05
DOAC
University of Vermont
Phase 3 Recruiting
NCT05683808 2026-01-30
VTE-POG
University of Vermont Medical Center
Phase 2 Recruiting
NCT07270263 2025-12-26
HEM-DOAC
Medical University of Gdansk
Phase NA Recruiting
NCT07189897 2025-10-08
Apixaban or Enoxaparin After Head and Neck Cancer Surgery
State University of New York - Upstate Medical University
Phase 4 Recruiting
NCT02066454 2025-08-13
MYELAXAT
University Hospital, Grenoble
Phase 3 Completed
NCT03045406 2025-06-24
CARAVAGGIO
Fadoi Foundation, Italy
Phase 3 Completed
NCT06603870 2025-05-30
STREAM-Line
Ottawa Hospital Research Institute
Phase 4 Recruiting
NCT06284343 2024-09-19
GynCAT
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
NCT04243122 2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2 Completed
NCT02744092 2023-10-03
CANVAS
Alliance Foundation Trials, LLC.
Phase NA Completed
NCT05461807 2022-10-26
H2H-OSCAR-US
Bayer
Completed
NCT03965741 2021-11-30
PRACTISE
Bayer
Completed
NCT04106700 2021-02-15
Prophylaxis With Apixaban in Transplant Eligible Patients With Multiple Myeloma Receiving Induction Therapy With IMiDs
Instituto de Investigacion Sanitaria La Fe
Phase 2 Terminated
NCT02585713 2020-08-04
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
Academic and Community Cancer Research United
Phase 3 Completed
NCT02366871 2020-03-31
Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy
University of Colorado, Denver
Phase 2 Completed
NCT02958969 2019-12-17
Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma
Dana-Farber Cancer Institute
Phase 4 Completed
NCT02048865 2018-11-20
AVERT
Ottawa Hospital Research Institute
Phase 2 Completed
NCT03083782 2017-10-11
ACT
Thomas Jefferson University
Phase 1 Completed